QMSR & ISO 13485 – What’s Changing and What You Need to Do
FDA is finally harmonizing its Quality System Regulation with ISO 13485 – and honestly, it was only a matter of time. Both standards grew from the same root (ISO 9001 back in 1996), just evolved separately for different markets. Now FDA is saying: enough parallel worlds.
What actually changes?
If you’re already ISO 13485 certified and selling in both the US and Europe, you’re mostly fine. Expect some terminology updates – FDA is dropping “safety and efficacy” in favor of “safety and performance,” and classic QSR acronyms like DHF, DMR, and DHR get replaced with ISO equivalents. A few US-specific requirements stay, though: UDI (21 CFR Part 830), high-risk device tracking (Part 821), and stricter labeling controls – because so many recalls come down to labeling mishaps.
Who needs to pay attention:
US-only companies without an ISO 13485-based QMS are facing the biggest gap. No CE Mark, no MDSAP, never looked at ISO 14971? Then you have real work ahead of you.
What to do now:
FDA starts inspecting under QMSR in February 2026. That’s not a lot of runway. Start with a gap analysis against ISO 13485, build an action plan, update your documentation top to bottom, and give yourself at least six months to actually live with the new system before the deadline. A mock inspection before go-live is highly recommended.
One more thing worth knowing: under QMSR, FDA gets access to records they couldn’t touch before – internal audits, supplier audits, management review minutes. And unlike Notified Body audits, FDA inspections are not time-bound. They can stay as long as they want.
Plan accordingly.
